Canada's IM Cannabis Q2 loss widens as revenue drops, finance expenses rise

IM Cannabis

13/08/2026 22:16

Overview
Canada-Israel medical cannabis platform's Q2 revenue fell sharply yr/yr, net loss widened
Company reported shareholders' deficit and cash declined to C$1.6 mln as of June 30, 2026
Gross profit and operating loss worsened compared to Q2 last year

Outlook
Company did not provide specific guidance for future quarters or the full year

Result Drivers
FINANCE EXPENSES - Finance expenses rose to C$2.9 mln from C$1.8 mln yr/yr, contributing to wider net loss
REVENUE DECLINE - Revenue fell to C$7.6 mln from C$12.7 mln yr/yr

Company press release: ID:nPnc8lSZxa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
 
C$7.59 mln
 
Q2 Loss Per Share
 
C$0.47
 

Reuters Recommended Reads
Aug 13 - Canada's Auxly Cannabis Q2 revenue rises on higher volume sales
Aug 13 - Canada's MediPharm Labs Q2 revenue rises 11% on international growth
Aug 11 - Canada's Organigram Q3 revenue beats on Sanity acquisition; CFO to exit

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)